Management of hepatitis c in kidney transplant patients: On the cusp of change

American Journal of Transplantation

Volumn 14, Issue 9, 2014, Pages 1955-1957

  Terrault, N A ^a   Stock, P G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLATASVIR; IMMUNOSUPPRESSIVE AGENT; INTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; COHORT ANALYSIS; CREATININE CLEARANCE; CRYOGLOBULINEMIA; DIALYSIS; END STAGE RENAL DISEASE; FEASIBILITY STUDY; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE DYSREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER FIBROSIS; LYMPHOCYTE DEPLETION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; COMPLICATION; DONOR; GRAFT REJECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

GRAFT REJECTION; HEPATITIS C; HIV INFECTIONS; HUMANS; KIDNEY TRANSPLANTATION; TISSUE DONORS;

EID: 84906237598     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12848     Document Type: Review

References (13)

1. Xia Y, Friedmann P, Yaffe H, Phair J, Gupta A, Kayler LK., Effect of HCV, HIV and coinfection in kidney transplant recipients: Mate kidney analyses. Am J Transplant 2014; 14: 2037-2047.
2. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G., Hepatitis C virus antibody status and survival after renal transplantation: Meta-analysis of observational studies. Am J Transplant 2005; 5: 1452-1461.
3. Cruzado JM, Carrera M, Torras J, Grinyo JM., Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001; 1: 171-178.
4. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ., Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185.
5. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363: 2004-2014.
6. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18: 716-726.
7. Miro JM, Montejo M, Castells L, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: A prospective and multicenter cohort study. Am J Transplant 2012; 12: 1866-1876.
8. Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9: 1946-1952.
9. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-263.
10. Goodkin D, Bieber B, Gillespie B, Robinson B, Jadoul M., Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol 2013; 38: 405-412.
11. Recommendations for Testing, Managing, Treating Hepatitis C. 2014. Available at: http://www.hcvguidelines.org/. Accessed March 21, 2014.
12. Lens S, Gambato M, Londono MC, Forns X., Interferon-free regimens in the liver-transplant setting. Semin Liver Dis 2014; 34: 58-71.
13. Kucirka LM, Peters TG, Segev DL., Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients. Am J Kidney Dis 2012; 60: 112-120.